Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
| Market Capitalization | $40.7176 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | 0 |
| Book Value | 0.131 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.11 |
| EBITDA | -25,294.068 |
| Profit Margin | 0 |
| Operating Margin TTM | -4.6041 |
| Return on Assets TTM | -0.2257 |
| Return on Equity TTM | -0.6378 |
| Revenue TTM | 6,209.843 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2021-06-30 | 0 | |||
| 2022-06-30 | 8.831 | 8.831 | 20,953.674 | |
| 2023-06-30 | 292.36 | 292.359 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2021-06-30 | 27.09 | 33.44 | 158.14 | 59 | 1 | |
| 2022-06-30 | 26,979.105 | 83,381.291 | 20,418.572 | 0 | 86,758.783 | |
| 2023-06-30 | 11,699.07 | 74,949.67 | 30,565.18 | 0 | 97,230.33 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2021-06-30 | -1,164.456 | -78.982 | 65.018 | 27.091 | ||
| 2022-06-30 | -30,420.008 | -9,906.823 | 26,952.014 | 27.091 | 26,979.105 | |
| 2023-06-30 | -34,611.194 | -23,201.8 | -15,280.04 | 26,979.105 | 11,699.066 |